[Infection due to herpes zoster and cryptococcus after initiating high-activity antiretroviral treatment].
Fonseca
E M
EM
Nuño
F J
FJ
García-Alcalde
M L
ML
Menéndez
M J
MJ
D017088:AIDS-Related Opportunistic Infections / Q000209:etiology*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004198:Disease Susceptibility; D015725:Fluconazole / Q000627:therapeutic use; D006562:Herpes Zoster / Q000209:etiology*; D014645:Herpesvirus 3, Human / Q000502:physiology; D006801:Humans; D008297:Male; D016919:Meningitis, Cryptococcal / Q000188:drug therapy / Q000209:etiology*; D012306:Risk; D014775:Virus Activation / Q000187:drug effects
D000935:Antifungal Agents; D015725:Fluconazole